Foley Hoag LLP represented leading regenerative medicine company Organogenesis Holdings Inc. (Nasdaq: ORGO) in the closing of its underwritten public offering of 19,916,708 shares of Class A common stock worth approximately $64.7 million in gross proceeds. Organogenesis Holdings intends to use the net proceeds from this offering, together with other available funds, for working capital and general corporate purposes, including, but not limited to, facility expansion and manufacturing enhancements, salesforce expansion and to conduct clinical studies of, obtain regulatory approvals and additional commercial insurance coverage for its products.
Organogenesis Holdings, located in Canton, Massachusetts, offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
The Foley Hoag team consisted of Stacie Aarestad, William Kolb, Ryan Rourke Reed, Caroline Samp, Anna Snook, Alissa Clarke, Nicholas Romanos, Philip Choi and Joshua Jarvis.